<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972842</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_PTCL1</org_study_id>
    <secondary_id>EudraCT 2008-006919-20</secondary_id>
    <nct_id>NCT00972842</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)</brief_title>
  <acronym>LenVoDex</acronym>
  <official_title>Phase I/II Trial of Lenalidomide in Combination With Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A standard therapy is neither established in first-line patients nor in relapsed patients
      with PTCL, and there is still an unmet medical need to identify novel efficacious and safe
      therapy regimens.

      The aim of this study is to evaluate the potential of a Lenalidomide plus Vorinostat and
      Dexamethasone combination therapy as an effective and safe therapeutic regimen, in the
      treatment of relapsed PTCL following failure of prior regimens.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to determine the maximum tolerated dose (MTD) of a Lenalidomide, Vorinostat, and Dexamethasone combination regimen in terms of occurrence of dose-limiting toxicities (DLT) at any dose level.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate of a combination therapy with Lenalidomide, Vorinostat, and Dexamethasone in a treatment refractory or relapsed population, defined as the percentage of patients achieving a complete response (CR) or partial response (PR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peripheral T-Cell Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat, Lenalidomide</intervention_name>
    <description>Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles
Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles</description>
    <other_name>Revlimid®</other_name>
    <other_name>Zolinza®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed PTCL according to WHO criteria who have received max. two
             previous treatments for PTCL

          -  Age ≥ 18 years.

          -  Adequate bone marrow function i.e. absolute neutrophile count of &gt; 1000/µl and
             thrombocytes &gt; 75,000/µl.

          -  Alkaline phosphatase and transaminases ≤ 2,5 x upper limit of normal (ULN)

          -  Total bilirubin ≤ 2,5 x ULN

          -  Creatinine clearance ≥ 50 ml/min

          -  Female subjects of childbearing potential† must: Understand that the study medication
             could have an expected teratogenic risk and agree to use, and be able to comply with,
             effective contraception and agree to have a medically supervised pregnancy test

          -  Male subjects must agree to use condoms and agree not to donate semen

        Exclusion Criteria:

          -  Prior history of malignancies, other than PTCL, unless the subject has been free of
             the disease for ≥ 3 years

          -  Prior allogeneic bone marrow transplant or plans to undergo autologous/ allogeneic
             bone marrow transplant within 4 weeks of the initiation of vorinostat administration

          -  Prior treatment with a HDAC inhibitor

          -  Prior treatment with Lenalidomide (patients previously treated with Thalidomide may be
             enrolled)

          -  Known history of Deep Vein Thrombosis (DVT) and/ or pulmonary embolism (PE)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Hopfinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanusch Krankenhaus Wien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>December 23, 2013</last_update_submitted>
  <last_update_submitted_qc>December 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTCL</keyword>
  <keyword>Peripheral T-Cell Non-Hodgkin's Lymphoma</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>Lenalidomid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

